Nobuhiko Tamura is Chairman and CEO of Sunovion Pharmaceuticals Inc., a global biopharmaceutical company with more than 1,600 employees focused on the innovative application of science and medicine to help people with serious medical conditions.
Sunovion's track record of discovery, development and commercialization of important psychiatric, neurological and respiratory therapies has included Latuda® (lurasidone HCI), Brovana® (arformoterol tartrate) and Aptiom® (eslicarbazepine acetate).
Mr. Tamura has served as the company's executive leader since 2014. Prior to his appointment as Chairman and CEO in 2016, he was Sunovion Vice Chair and President. Mr. Tamura also serves as a Senior Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. Group, the parent company of Sunovion.
Previously, as Chief Scientific Officer of Sunovion, Mr. Tamura led the New Drug Application (NDA) submission of LATUDA, which was approved in the U.S. in 2010 for the treatment of schizophrenia in adults. He was President of Dainippon Sumitomo Pharma America prior to its integration with Sepracor to form Sunovion.
Mr. Tamura began his career as a researcher at Sumitomo Chemical Co., Ltd. in 1982 and was one of the first employees of Sumitomo Pharmaceutical Co., Ltd. After six years in the discovery lab, he was business development liaison in New York and served as the company's U.S. representative. Earlier, he led multiple R&D programs and fostered the development of new chemical entities for the treatment of central nervous system and other disorders.
He serves on the Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA).
Mr. Tamura earned his master's degree in pharmacy from Tohoku University and his bachelor's degree in pharmacy from the Tokyo University of Science.